Literature DB >> 6086885

Alpha-1 adrenoceptor selectivity of phenoxybenzamine in the rat kidney.

D D Smyth, S Umemura, W A Pettinger.   

Abstract

The dose-dependent selectivity of an irreversible binding antagonist, phenoxybenzamine (POB), for renal alpha-1 adrenoceptors, was biochemically and physiologically characterized. Receptors were quantified with the radioligands [3H]prazosin and [3H]rauwolscine for alpha-1 and alpha-2 adrenoceptors, respectively. Alpha-1 adrenoceptor function was quantified by the shift of the norepinephrine and phenylephrine pressor response in vivo and the vasoconstrictor response in the isolated perfused kidney preparation. A renal alpha-2 adrenoceptor response was demonstrated by showing that epinephrine could reverse the effect of vasopressin on water and sodium in the presence of beta blockade and alpha-1 destruction by POB. Doses of POB from 0.1 to 10.0 mg/kg progressively reduced [3H]prazosin binding to renal alpha-1 adrenoceptors until there was no specific binding at the 10.0-mg/kg dose. At this dose more than 60% of [3H]rauwolscine binding to renal alpha-2 adrenoceptors was still present. POB 1.0 mg/kg/hr decreased specific binding to renal alpha-1 adrenoceptors by approximately 40% (P less than .05) but reduced the alpha-1 adrenoceptor-induced vasoconstriction in the nonrecirculating isolated perfused kidney to 10 to 20% of the control. This was the maximal dose of POB studied which did not affect the alpha-2 adrenoceptor-induced antagonism of vasopressin. Higher doses of POB (3.0 mg/kg/hr) demonstrated some alpha-2 adrenoceptor binding as indicated by an attenuation of the antagonism by alpha-2 adrenoceptors. Thus, POB displays selectivity for renal alpha-1 over alpha-2 adrenoceptors. Our data indicate that a dose of 1.0 mg/kg/hr of POB will leave alpha-2 adrenoceptors intact while functionally incapacitating alpha-1 adrenoceptors to 10 to 20% of the control value.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086885

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Hypertension's 3 Dilemmas and 3 Solutions: Pharmacology of the Kidney in Hypertension.

Authors:  William A Pettinger
Journal:  J Cardiovasc Pharmacol       Date:  2017-03       Impact factor: 3.105

2.  H1-receptor reserves in guinea-pig left atria, trachea and pig coronary artery as identified by phenoxybenzamine.

Authors:  E Rappen-Cremer; U Borchard; D Hafner; F Berger
Journal:  Agents Actions       Date:  1989-11

3.  Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers.

Authors:  H Lavon; P Matzner; A Benbenishty; L Sorski; E Rossene; R Haldar; E Elbaz; J P Cata; V Gottumukkala; S Ben-Eliyahu
Journal:  Br J Anaesth       Date:  2017-11-23       Impact factor: 9.166

4.  Stimulation of alpha 1-adrenoceptors in rat kidney mediates increased inositol phospholipid hydrolysis.

Authors:  C B Neylon; R J Summers
Journal:  Br J Pharmacol       Date:  1987-06       Impact factor: 8.739

5.  Splenorenal reflex modulates renal blood flow in the rat.

Authors:  Shereen M Hamza; Susan Kaufman
Journal:  J Physiol       Date:  2004-04-16       Impact factor: 5.182

6.  Renal and iliac vascular effects of dopamine in the anaesthetized rat.

Authors:  M Schmidt; E Giesen-Crouse; J L Imbs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-04       Impact factor: 3.000

Review 7.  α 2-Adrenoceptors: Challenges and Opportunities-Enlightenment from the Kidney.

Authors:  William A Pettinger; Edwin K Jackson
Journal:  Cardiovasc Ther       Date:  2020-04-29       Impact factor: 3.023

8.  A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo.

Authors:  Aaron Petty; Eugene Myshkin; Haina Qin; Hong Guo; Hui Miao; Gregory P Tochtrop; Jer-Tsong Hsieh; Phillip Page; Lili Liu; Daniel J Lindner; Chayan Acharya; Alexander D MacKerell; Eckhard Ficker; Jianxing Song; Bingcheng Wang
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.